Skip to content
Open Access
  • Home
  • Collections
    • High Impact Articles
    • Jawi Collection
    • Malay Medicine
    • Forensic
  • Search Options
    • UiTM Open Access
    • Search by UiTM Scopus
    • Advanced Search
    • Search by Category
  • Discovery Service
    • Sources
    • UiTM Journals
    • List UiTM Journal in IR
    • Statistic
  • About
    • Open Access
    • Creative Commons Licenses
    • COKI | Malaysia Open Access
    • User Guide
    • Contact Us
    • Search Tips
    • FAQs
Advanced
  • Search
  • Burosumab treatment in a child...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Export Ready — 
Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report

Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report

Show other versions (1)
Bibliographic Details
Main Authors: Manal Khadora, Zulf Mughal
Format: Article
Language:English
Published: Elsevier 2021-04-01
Series:Bone Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2352187221001017
  • Holdings
  • Description
  • Other Versions (1)
  • Similar Items
  • Staff View

Internet

http://www.sciencedirect.com/science/article/pii/S2352187221001017

Similar Items

  • Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report
    by: Manal Khadora, et al.
    Published: (2021-12-01)
  • Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia
    by: Silvia Martín Ramos, et al.
    Published: (2020-02-01)
  • Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
    by: Aaron Schindeler, et al.
    Published: (2020-05-01)
  • Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy
    by: Avivit Brener, et al.
    Published: (2021-03-01)
  • The recommended starting dose of 0.4mg/kg burosumab is insufficient for most children with X-linked hypophosphatemia (XLH) - Results from the first treated patients in Sweden
    by: Sigrun Hallgrimsdottir, et al.
    Published: (2020-10-01)

© 2020 | Services hosted by the Perpustakaan Tun Abdul Razak, | Universiti Teknologi MARA | Disclaimer


Loading...